相关实验视频
Updated: Jul 5, 2025
07:35
Gene Transfer for Ischemic Heart Failure in a Preclinical Model
Published on: May 15, 2011
12.9K
选择性SERCA2a激活剂作为慢性心力衰竭治疗的候选者
Martina Arici1, Shih-Che Hsu2, Mara Ferrandi3
1Department of Biotechnology and Biosciences, Università Degli Studi di Milano-Bicocca, P.Za Della Scienza 2, 20126, Milan, Italy.
Journal of translational medicine
|January 19, 2024
概括
一种新的药物,化合物8,通过刺激质网膜Ca2+ ATPase (SERCA2a) 活性,有效地改善心力衰竭. 这种基于机制的疗法对慢性心力衰竭治疗具有很好的耐受性.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 分子生物学分子生物学
背景情况:
- 质网膜Ca2+ ATPase (SERCA2a) 功能障碍是心力衰竭 (HF) 相关的腹功能障碍的一个关键因素.
- 激发SERCA2a是一种潜在的基于HF的机制治疗策略.
- 现有的治疗方法,如伊斯塔洛キシ姆及其代谢物PST3093,对慢性HF治疗有局限性.
研究的目的:
- 描述化合物8,一种新的PST3093衍生物,用于潜在的慢性口腔心力衰竭治疗.
- 评估化合物8在恢复SERCA2a活性和改善心脏功能的有效性和安全性.
主要方法:
- 化合物8的效果被评估在接受过 estreptozotocin 治疗的老鼠中,这是扩张功能障碍的一个模型.
- 在体外和体内研究评估了SERCA2a刺激,心脏功能通过心声学和电生理学效应.
- 急性和慢性服用途径 (静脉注射) 和口腔) 被调查.
主要成果:
- 化合物8增强了心脏肌细胞中的SR Ca2+区分.
- 在体内研究表明,在急性和慢性管理后,透支功能显著改善.
- 化合物8对心脏电活动没有任何不良影响,并且在小鼠中表现出良好的耐受性.
结论:
- 化合物8显示出作为慢性心力衰竭的安全和选择性口服治疗剂的潜力.
- 通过化合物8恢复SERCA2a活性提供了一种基于机制的治疗心力衰竭治疗方法.
相关概念视频
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
432
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
432
01:26Heart Failure Drugs: Inotropic Agents
591
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
591
01:22Heart Failure Drugs: β-Blockers
341
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
341
01:22Heart Failure Drugs: Diuretics
384
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
384
01:17Pathophysiology of Heart Failure
1.6K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.6K
01:27Transducer Mechanism: Enzyme-Linked Receptors
2.5K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.5K